MX2022016591A - Moléculas de anticuerpo contra april y usos de las mismas. - Google Patents

Moléculas de anticuerpo contra april y usos de las mismas.

Info

Publication number
MX2022016591A
MX2022016591A MX2022016591A MX2022016591A MX2022016591A MX 2022016591 A MX2022016591 A MX 2022016591A MX 2022016591 A MX2022016591 A MX 2022016591A MX 2022016591 A MX2022016591 A MX 2022016591A MX 2022016591 A MX2022016591 A MX 2022016591A
Authority
MX
Mexico
Prior art keywords
antibody molecules
april
treat
disclosed
prevent
Prior art date
Application number
MX2022016591A
Other languages
English (en)
Spanish (es)
Inventor
Zachary Shriver
Gregory Babcock
James R Myette
Boopathy Ramakrishnan
Hedy Adari-Hall
Jill Yarbrough
Asher Schachter
Karthik Viswanathan
Andrew M Wollacott
Mohit Mathur
Original Assignee
Visterra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra Inc filed Critical Visterra Inc
Publication of MX2022016591A publication Critical patent/MX2022016591A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022016591A 2020-06-24 2021-06-24 Moléculas de anticuerpo contra april y usos de las mismas. MX2022016591A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063043558P 2020-06-24 2020-06-24
US202063091002P 2020-10-13 2020-10-13
US202163136950P 2021-01-13 2021-01-13
US202163195527P 2021-06-01 2021-06-01
PCT/US2021/038924 WO2021262999A1 (en) 2020-06-24 2021-06-24 Antibody molecules to april and uses thereof

Publications (1)

Publication Number Publication Date
MX2022016591A true MX2022016591A (es) 2023-04-20

Family

ID=77022225

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016591A MX2022016591A (es) 2020-06-24 2021-06-24 Moléculas de anticuerpo contra april y usos de las mismas.

Country Status (11)

Country Link
US (1) US20260116988A1 (cg-RX-API-DMAC7.html)
EP (1) EP4172206A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023531722A (cg-RX-API-DMAC7.html)
KR (1) KR20230042273A (cg-RX-API-DMAC7.html)
AU (1) AU2021297315A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026639A2 (cg-RX-API-DMAC7.html)
CA (1) CA3187823A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022016591A (cg-RX-API-DMAC7.html)
PH (1) PH12023550198A1 (cg-RX-API-DMAC7.html)
TW (1) TW202216195A (cg-RX-API-DMAC7.html)
WO (1) WO2021262999A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170145086A1 (en) 2015-11-25 2017-05-25 Visterra, Inc. Antibody molecules to april and uses thereof
AU2023262513A1 (en) * 2022-04-25 2024-12-05 Visterra, Inc. Antibody molecules to april and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US20170145086A1 (en) * 2015-11-25 2017-05-25 Visterra, Inc. Antibody molecules to april and uses thereof
CA3032820A1 (en) 2016-08-02 2018-03-22 Visterra, Inc. Engineered polypeptides and uses thereof

Also Published As

Publication number Publication date
KR20230042273A (ko) 2023-03-28
TW202216195A (zh) 2022-05-01
JP2023531722A (ja) 2023-07-25
WO2021262999A1 (en) 2021-12-30
US20260116988A1 (en) 2026-04-30
CA3187823A1 (en) 2021-12-30
AU2021297315A1 (en) 2023-02-02
PH12023550198A1 (en) 2024-06-24
EP4172206A1 (en) 2023-05-03
BR112022026639A2 (pt) 2023-05-09

Similar Documents

Publication Publication Date Title
ZA202208280B (en) Antibody molecules to c5ar1 and uses thereof
ZA201803366B (en) Antibody molecules to april and uses thereof
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
WO2019232244A3 (en) Antibody molecules to cd73 and uses thereof
PH12020550141A1 (en) Antibody molecules to cd138 and uses thereof
PH12018501206A1 (en) Antibody molecules to pd-1 and uses thereof
PH12016501545A1 (en) Antibody molecules to lag-3 and uses thereof
WO2017181098A3 (en) Antibody molecules to zika virus and uses thereof
WO2022046922A3 (en) Antibody molecules that bind to nkp30 and uses thereof
PH12016501456A1 (en) Antibody molecules to pd-1 and uses thereof
WO2017019894A8 (en) Combination therapies comprising antibody molecules to lag-3
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
WO2020257289A3 (en) Humanized antibody molecules to cd138 and uses thereof
JO3567B1 (ar) جزيئات جسم مضاد لـ tim-3 واستخداماتها
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
PH12023550198A1 (en) Antibody molecules to april and uses thereof
PH12021552414A1 (en) Anti fgf23 antibody
PH12019500677A1 (en) Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
WO2022026592A3 (en) Antibody molecules to coronavirus and uses thereof
MX2019007356A (es) Polipeptidos de union y metodos para fabricarlos.
PH12020552202A1 (en) Antibody molecules to complement component 5 and uses thereof
EA202090891A1 (ru) Молекулы антител против cd138 и их применение
HK1232551A1 (en) Antibody moleules to dengue virus and uses thereof